Eligible patients with bleeding hemorrhoids of grade 2-3 are randomized to test-1 product (PP110 Gel), test-2 product (PP-110 medicated wipes) or control (Preparation-H cream). Test product usage: once daily, about 1-5 minutes prior to first bowel movement. Control product usage: according to label, 3-4 times daily application to rectal region. At the end of each day, subject fills a questionnaire regarding bleeding, pain, discharge, swelling, itching, discomfort and painkiller usage. Treatment is for two weeks, after which subjects fill a feedback questionnaire addressing treatment efficacy and subject satisfaction. Also, at the end of two weeks, subjects are examined by study physician who assesses hemorrhoid severity.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
101
Unnamed facility
Kfar Saba, Israel
Unnamed facility
Kiryat Ono, Israel
Unnamed facility
Modiin, Israel
Unnamed facility
Ramat Gan, Israel
Unnamed facility
Tel Aviv, Israel
Bleeding / Spotting
Time frame: 14 days
Pain
Time frame: 14 days
Discharge
Time frame: 14 days
Itching
Time frame: 14 days
Swelling
Time frame: 14 days
Discomfort
Time frame: 14 days
Painkillers usage
Time frame: 14 days
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.